

# RECOVERY

Randomised Evaluation of COVID-19 Therapy

## Statistical Analysis Plan

Version 4.0

Date: 20 September 2022

Aligned with protocol version: 25.0, 23 May 2022

IRAS no: 281712

REC ref: EE/20/0101

ISRCTN: 50189673

EudraCT: 2020-001113-21

Nuffield Department of  
POPULATION HEALTH



## Table of Contents

Table of Contents.....	2
Abbreviations.....	6
List of authors and reviewers (up to and including SAP version 1.1).....	7
List of authors and reviewers (version 2.0 onwards).....	7
Roles and responsibilities.....	8
1 Introduction.....	9
2 Background information.....	10
2.1 Rationale.....	10
2.2 Objectives of the trial.....	10
2.2.1 Primary objective and secondary outcomes for COVID-19 comparisons.....	10
2.2.2 Primary and secondary outcomes for influenza comparisons.....	10
2.3 Trial design.....	10
2.4 Eligibility.....	11
2.4.1 Inclusion criteria.....	11
2.4.2 Exclusion criteria.....	11
2.4.3 Randomisation on more than one occasion.....	11
2.5 Treatments.....	11
<i>COVID-19 Comparisons</i> .....	11
2.5.1 Main randomisation part A (enrolment closed):.....	11
2.5.2 Main randomisation part B (enrolment closed):.....	12
2.5.3 Main randomisation part C (enrolment closed):.....	12
2.5.4 Main randomisation part D (enrolment closed):.....	12
2.5.5 Main randomisation part E (enrolment modified on advice of DMC):.....	13
2.5.6 Main randomisation part F:.....	13
2.5.7 Main randomisation part J:.....	13
2.5.8 Main randomisation part K:.....	13
2.5.9 Main randomisation part L:.....	14
2.5.10 Second randomisation for adults with progressive COVID-19 ( <b>enrolment closed</b> ) 14	
<i>Influenza Comparisons (enrolment not commenced)</i> .....	14
2.5.11 Main randomisation part G ( <b>enrolment not commenced</b> ):.....	14
2.5.12 Main randomisation part H ( <b>enrolment not commenced</b> ):.....	15
2.5.13 Main randomisation part I ( <b>enrolment not commenced</b> ):.....	15
2.6 Definitions of outcomes.....	15
2.6.1 Primary outcome.....	15

2.6.2	Secondary clinical outcomes.....	15
2.6.3	Subsidiary clinical outcomes.....	15
2.6.4	Virological outcomes .....	16
2.6.5	Safety outcomes .....	16
2.6.6	Detailed derivation of outcomes .....	16
2.9	Randomisation .....	17
	<i>COVID-19 treatment comparisons</i> .....	17
2.9.1	Main randomisation part A (enrolment closed) .....	17
2.9.2	Main randomisation part B (enrolment closed) .....	18
2.9.3	Main randomisation part C (enrolment closed) .....	18
2.9.4	Main randomisation part D (enrolment closed).....	18
2.9.5	Main randomisation part E (enrolment modified on advice of DMC).....	18
2.9.6	Main randomisation part F .....	19
2.9.7	Main randomisation part J.....	19
2.9.8	Main randomisation part K.....	19
2.9.9	Main randomisation part L .....	19
2.9.10	Second randomisation for adults with progressive COVID-19 (enrolment closed) 19	
	<i>Influenza treatment comparisons [enrolment not commenced]</i> .....	20
2.9.11	Main randomisation part G .....	20
2.9.12	Main randomisation part H.....	20
2.9.13	Main randomisation part I .....	20
2.10	Blinding.....	20
2.11	Data collection schedule.....	20
2.12	Data monitoring.....	21
2.13	Trial reporting.....	21
3	Analysis populations .....	21
3.1	Population definitions .....	21
4	Descriptive analyses.....	22
4.1	Participant throughput.....	22
4.2	Baseline comparability of randomised groups .....	22
	<i>COVID-19 treatment comparisons</i> .....	22
4.2.1	Main randomisation – COVID-19 comparisons (parts A, B, C, D, E, F, J, K, L)....	22
4.2.2	Second randomisation .....	23
	<i>Influenza treatment comparisons</i> .....	23
4.2.3	Main randomisation – influenza comparisons (parts G, H, I) .....	23

4.3	Completeness of follow-up .....	23
4.4	Adherence to treatment .....	24
5	Comparative analyses at 28 DAYS .....	24
5.1	Main randomisation (all parts).....	24
5.1.1	Primary and secondary outcome.....	24
5.1.2	Subsidiary clinical outcomes.....	25
5.1.3	Virological outcomes .....	26
5.2	Second randomisation .....	26
5.3	Pre-specified subgroup analyses.....	26
5.4	Adjustment for baseline characteristics .....	27
5.5	Sensitivity analyses.....	27
5.6	Other exploratory analyses .....	28
5.7	Significance levels and adjustment of p-values for multiplicity.....	28
5.8	Statistical software employed.....	28
5.9	Data standards and coding terminology.....	28
6	Safety data .....	28
6.1	Cause-specific mortality .....	29
6.2	Major cardiac arrhythmia.....	29
6.3	Major bleeding .....	29
6.4	Early safety of anti-coronavirus antibody-based therapy.....	29
6.5	Other infections.....	29
6.6	Metabolic, kidney and liver complications .....	29
6.7	Seizures .....	30
6.8	Infusion reactions to sotrovimab .....	30
7	Additional POST-HOC exploratory analysis.....	30
8	Differences from protocol .....	30
9	EARLY PHASE ASSESSMENTS.....	31
9.1	Definitions of clinical outcomes .....	31
9.1.1	Primary outcome .....	31
9.1.2	Secondary clinical outcomes.....	31
9.1.3	Subsidiary clinical outcomes.....	31
9.1.4	Safety outcomes .....	31
9.2	Baseline comparability of randomised groups .....	31
9.3	Comparative analysis .....	31
9.3.1	Primary outcome .....	31

9.3.2.2	Improvement in clinical status at day 10 .....	32
9.3.2.3	Blood C-reactive protein at day 5 .....	32
9.3.2.4	S/F <sub>94</sub> ratio at day 5 .....	32
9.3.3	Safety outcomes .....	33
10	6-MONTH and longer-term ASSESSMENTS .....	34
10.1	Objectives .....	34
10.2	Comparative analyses at 6 months .....	34
10.2.1	Primary outcome .....	34
10.2.2	Pre-specified subgroup analyses .....	34
10.2.3	Adjustment for baseline characteristics .....	35
10.2.4	Sensitivity analyses .....	35
10.2.5	Significance levels and adjustment of p-values for multiplicity .....	35
10.3	Safety data .....	35
10.4	Other exploratory analyses .....	35
10.5	Censoring and analysis .....	35
11	References .....	37
11.1	Trial documents .....	37
11.2	Other references .....	37
12	APPENDIX I: Analyses of REGEN-COV2 .....	38
12.1	Background & rationale .....	38
12.2	Analytical plan .....	38
12.3	References .....	39
13	APPENDIX II: Analyses of Sotrovimab and other anti-virals for COVID-19 .....	41
13.1	Background & rationale .....	41
13.2	References .....	42
14	Approval .....	43
15	Document history .....	44

## Abbreviations

ADaM	Analysis Data Model
AE	Adverse event
CDISC	The Clinical Data Interchange Standards Consortium
CI	Confidence interval
COVID	Coronavirus-induced disease
CPAP	Continuous Positive Airway Pressure
CRP	C-reactive protein
DMC	Data Monitoring Committee
ECMO	Extra Corporeal Membrane Oxygenation
eCRF	Electronic case report form
ICD	International Classification of Diseases
ICNARC	Intensive Care National Audit and Research Centre
ITT	Intention to treat
MedDRA	Medical Dictionary for Regulatory Activities
OPCS-4	National Health Service OPCS Classification of Interventions and Procedures version 4
SARS	Severe acute respiratory syndrome
SARS-CoV-2	Severe acute respiratory syndrome coronavirus 2
S/F <sub>94</sub> ratio	Ratio of peripheral oxygen saturation to fractional inspired oxygen concentration when peripheral oxygen saturation at or below 94%
SSAR	Suspected serious adverse reaction
SUSAR	Suspected unexpected serious adverse reaction
TSC	Trial Steering Committee

## List of authors and reviewers (up to and including SAP version 1.1)

### *Authors*

Dr Louise Linsell, Lead Trial Statistician, Nuffield Department of Population Health (NDPH), University of Oxford

Jennifer Bell, Trial Statistician, NDPH, University of Oxford

### *Reviewers*

Professor Jonathan Emberson, Data Monitoring Committee (DMC) Statistician, NDPH, University of Oxford (prior to unblinded interim analysis of trial outcomes)

Professor Richard Haynes, Clinical Coordinator, NDPH, University of Oxford

Professor Peter Horby, Chief Investigator (CI), Nuffield Department of Medicine, University of Oxford

Professor Thomas Jaki, TSC Member, Department of Mathematics and Statistics, Lancaster University

Associate Professor Edmund Juszczak, TSC Member, NDPH, University of Oxford (until 6 July 2020)

Professor Martin Landray, Deputy CI, NDPH, University of Oxford

Professor Alan Montgomery, TSC Member, Nottingham Clinical Trials Unit, University of Nottingham

Dr Natalie Staplin, DMC Statistician, NDPH, University of Oxford (prior to unblinded interim analysis of trial outcomes)

## List of authors and reviewers (version 2.0 onwards)

Professor Edmund Juszczak, TSC Member (University of Nottingham from 6 July 2020)

Professor Alan Montgomery (University of Nottingham), TSC Member

Professor Thomas Jaki (University of Cambridge) co-investigator and TSC Member

Enti Spata, Trial Statistician, NDPH, University of Oxford (until 4 March 2022)

Professor Richard Haynes, Clinical Coordinator, NDPH, University of Oxford

Professor Martin Landray, Deputy CI, NDPH, University of Oxford

Professor Peter Horby, CI, Nuffield Department of Medicine, University of Oxford

## Roles and responsibilities

### *Trial Statisticians*

*Until 30 September 2020:* Dr Louise Linsell and Jennifer Bell (NDPH, University of Oxford)

Role: To develop the statistical analysis plan (blinded to trial allocation) and conduct the final comparative analyses for Lopinavir-Ritonavir, Corticosteroid (dexamethasone) and Hydroxychloroquine (main randomisation part A).

*From 1 October 2020 until 4 March 2022:* Enti Spata (NDPH, University of Oxford)

Role: To develop the statistical analysis plan (blinded to trial allocation) and conduct the final comparative analyses for all other treatment arms in this period.

*From 1 April 2022:* Professor Jonathan Emberson and Dr Natalie Staplin (NDPH, University of Oxford)

Role: To develop the statistical analysis plan (only for those aspects to which they are currently blinded) and to conduct the final comparative analyses on completion.

### *Data Monitoring Committee (DMC) Statisticians (non-voting)*

Professor Jonathan Emberson and Dr Natalie Staplin (NDPH, University of Oxford)

Role: To conduct regular interim analyses for the DMC. Other contributions are restricted until completion of each comparison.

### *Statisticians on the Trial Steering Committee (TSC)*

Professor Edmund Juszczak (University of Nottingham), Professor Alan Montgomery (University of Nottingham), and Professor Thomas Jaki (University of Cambridge)

Role: Major organisational and policy decisions, and scientific advice; blinded to treatment allocation.

### *Trial IT systems & Programmers*

Andy King, David Murray, Richard Welsh (NDPH, University of Oxford)

Role: To generate and prepare reports monitoring the randomisation schedule. To supply data snapshots for interim and final analysis. Responsibility for randomisation system, clinical databases and related activities.

Bob Goodenough (NDPH, University of Oxford)

Role: Validation of IT systems

Dr Will Stevens, Karl Wallendzus (NDPH, University of Oxford)

Role: To produce analysis-ready datasets according to CDISC standards.

## 1 INTRODUCTION

This document details the proposed presentation and analysis for the main paper(s) reporting results from the multicentre randomised controlled trial RECOVERY (ISRCTN50189673) to investigate multiple treatments on major outcomes in inpatients for COVID-19 (clinically suspected or laboratory confirmed).

The results reported in these papers will follow the strategy set out here, which adheres to the guidelines for the content of a statistical analysis plan (SAP).<sup>1</sup> Any subsequent analyses of a more exploratory nature will not be bound by this strategy.

Suggestions for subsequent analyses by oversight committees, journal editors or referees, will be considered carefully in line with the principles of this analysis plan.

Any deviations from the statistical analysis plan will be described and justified in the final report. The analysis will be carried out by identified, appropriately qualified and experienced statisticians, who will ensure the integrity of the data during their processing.

This SAP is based on multiple versions of the protocol. All regulatory documents can be found in the RECOVERY trial directory: <https://www.recoverytrial.net/for-site-staff/site-set-up-1/regulatory-documents>.

SAP versions 1.0 & 1.1 applied to the first three principal comparisons (hydroxychloroquine, dexamethasone, and lopinavir-ritonavir versus no additional treatment respectively), for which data matured in the first UK wave of the pandemic. However, due to its later introduction, enrolment of patients in the azithromycin arm was much slower. Over time, factorial randomisations and a second randomisation have been added, introducing new treatment arms including convalescent plasma, tocilizumab, synthetic neutralizing antibodies, and aspirin. Version 2.0 of the SAP was produced in response to these changes, combined with the fact that use of corticosteroids (one of the original treatment arms) is now the usual standard of care for many patients. SAP version 3.0 included revisions for REGEN-COV2 (casirivimab+imdevimab), early phase assessments, and 6 month follow-up.

SAP version 4.0 now includes the following revisions:

- Additional COVID-19 comparisons: sotrovimab, molnupiravir, and Paxlovid (nirmatrelvir/ritonavir)
- Addition of influenza comparisons: baloxavir, oseltamivir, low-dose corticosteroids
- Addition of virology outcomes
- Changes to 6 month follow-up analyses

The primary outcome for children will be the duration of hospitalisation (as death is an extremely rare event). The analyses of data from children will be specified in a separate Statistical Analysis Plan.

## 2 BACKGROUND INFORMATION

### 2.1 Rationale

In early 2020, as the protocol was being developed, there were no approved treatments for COVID-19. The aim of the trial is to provide reliable evidence on the efficacy of candidate therapies (including re-purposed and novel drugs) for suspected or confirmed COVID-19 infection on major outcomes in hospitalised adult patients receiving standard care.

In late 2021, the protocol was extended to include evaluation of potential treatments for influenza occurring in isolation or in combination with COVID-19 (protocol version 19 onwards) and this was approved by MHRA and the ethics committee. However, the Medical Research Council and National Institute for Health and Care Research instructed the Co-lead Investigators that the current grants for RECOVERY could not be used to support the enrolment of participants to the influenza treatment comparisons. Consequently, at the time of finalising the current version of the SAP (version 4.0), enrolment remains restricted to the evaluation of treatments for COVID-19. Aspects of this SAP that are specific to influenza will be reviewed and may be revised if/when enrolment to these comparisons opens (and prior to any unblinded analyses of those comparisons).

### 2.2 Objectives of the trial

#### 2.2.1 *Primary and secondary objectives for COVID-19 comparisons*

The primary objective is to provide reliable estimates of the effect of study treatments on all-cause mortality within 28 days of the relevant randomisation. The secondary objectives are to investigate the effect of study treatments on the duration of hospital stay and on the combined endpoint of use of invasive mechanical ventilation (including Extra Corporal Membrane Oxygenation [ECMO]) or death.

#### 2.2.2 *Primary and secondary objectives for influenza comparisons*

The co-primary objectives are to provide reliable estimates of the effect of study treatments on (a) all-cause mortality within 28 days of the relevant randomisation and (b) the duration of hospital stay. The secondary objective is to investigate the effect of study treatments on the combined endpoint of use of invasive mechanical ventilation (including Extra Corporal Membrane Oxygenation [ECMO]) or death.

### 2.3 Trial design

This is a multi-centre, multi-arm, adaptive, open label, randomised controlled trial with three possible stages of randomisation, as described below. The trial is designed with streamlined processes in order to facilitate rapid large-scale recruitment with minimal data collection.

## 2.4 Eligibility

### 2.4.1 *Inclusion criteria*

Patients are eligible for the trial if all of the following are true:

- Hospitalised
- Viral pneumonia syndrome
- Confirmed SARS-Cov-2 infection and/or influenza A or B infection
- No medical history that might, in the opinion of the attending clinician, put the patient at significant risk if they were to participate in the trial.

### 2.4.2 *Exclusion criteria*

If one or more of the active drug treatments is not available at the hospital or is believed, by the attending clinician, to be contraindicated (or definitely indicated) for the specific patient, then this fact will be recorded via the web-based form prior to randomisation; random allocation will then be between the remaining arms. Details of specific contraindications and cautions for each treatment are listed in Appendix 2 of the protocol.

### 2.4.3 *Randomisation on more than one occasion*

From protocol version 21.1, patients who have been previously recruited into RECOVERY are eligible to be recruited again as long as their previous randomisation was >6 months ago. Patients will not be recruited into the same randomised comparison on more than one occasion, regardless of the time interval.

## 2.5 Treatments

All patients will receive standard management for the participating hospital. The main randomisation will be between the following treatment arms (although not all arms may be available at any one time). The doses listed are for adults; paediatric dosing is described in the protocol.

### *COVID-19 Comparisons*

#### 2.5.1 *Main randomisation part A (enrolment closed):*

- **No additional treatment**
- **Lopinavir 400mg-Ritonavir 100mg** by mouth (or nasogastric tube) every 12 hours for 10 days. [Introduced in protocol version 1.0; **enrolment closed** 29 June 2020]
- **Corticosteroid** in the form of dexamethasone, administered as an oral liquid or intravenous preparation 6 mg once daily for 10 days. In pregnancy, prednisolone 40 mg administered by mouth (or intravenous hydrocortisone 80 mg twice daily) should be used instead. [Introduced in protocol version 1.0; **enrolment closed to adults** 8 June 2020]
- **Hydroxychloroquine** by mouth for 10 days (4 doses in first 24 hours and 1 dose every 12 hours for 9 days). [Introduced in protocol version 2.0; **enrolment closed** 5 June 2020]

- **Azithromycin 500mg** by mouth (or nasogastric tube) or intravenously once daily for a total of 10 days. [Introduced in protocol version 3.0; **enrolment closed** 27 November 2020]
- **Colchicine** by mouth for 10 days (1.5 mg in first 12 hours then 0.5 mg twice daily). [Introduced in protocol version 12.0; **enrolment closed** 5 March 2021.]
- **Dimethyl fumarate** 120 mg every 12 hours for 4 doses followed by 240 mg every 12 hours by mouth for 8 days (10 days in total). [Introduced in protocol version 14.0 as Early Phase Assessment; **enrolment closed** 19 November 2021.]

### 2.5.2 *Main randomisation part B (enrolment closed):*

In a factorial design, eligible patients may be randomised to the arms below. The doses listed are for adults; paediatric dosing is described in the protocol.

- **No additional treatment**
- **Convalescent plasma** Single unit of ABO compatible convalescent plasma (275mls  $\pm$  75 mls) intravenous per day on study days 1 (as soon as possible after randomisation) and 2 (with a minimum of 12-hour interval between 1st and 2nd units). ABO identical plasma is preferred if available. The second transfusion should not be given if patient has a suspected serious adverse reaction during or after the first transfusion. [Introduced in protocol version 6.0; **enrolment closed** 15 January 2021]
- **Synthetic neutralising antibodies** (REGEN-COV2; adults and children aged  $\geq 12$  years only - children who weigh  $< 40$ kg will also not be eligible for this treatment). A single dose of REGN10933 + REGN10987 8 g (4 g of each monoclonal antibody) in 250ml 0.9% saline infused intravenously over 60 minutes  $\pm$  15 minutes as soon as possible after randomisation. [Introduced in protocol version 9.1; **enrolment closed** 22 May 2021]

### 2.5.3 *Main randomisation part C (enrolment closed):*

In a factorial design, eligible patients may be randomised to the arms below. The dose listed is for adults; children are excluded from this comparison.

- **No additional treatment**
- **Aspirin** 150 mg by mouth (or nasogastric tube) or per rectum once daily until discharge. [Introduced in protocol version 10.1; **enrolment closed** 21 March 2021]

### 2.5.4 *Main randomisation part D (enrolment closed):*

In a factorial design, eligible patients may be randomised to the arms below. The dose listed is for adults; children  $< 2$  years old or with PIMS-TS are excluded from this comparison.

- **No additional treatment**

- **Baricitinib** 4 mg by mouth (or nasogastric tube) once daily for 10 days. [Introduced in protocol version 13.0; **enrolment closed** 29 December 2021]

#### 2.5.5 *Main randomisation part E (enrolment modified on advice of DMC):*

In a factorial design, eligible patients may be randomised to the arms below. The dose listed is for adults; children <18 years old are excluded from this comparison.

- **No additional treatment**
- **High-dose corticosteroids** dexamethasone 20 mg once daily for 5 days, followed by dexamethasone 10 mg once daily for 5 days. [Introduced outside UK in protocol version 13.0 and within UK in protocol version 20.0; eligibility criteria modified in protocol version 25.0; **enrolment ongoing**

On 11 May 2022, the RECOVERY DMC advised, “*For patients being considered for treatment with high dose dexamethasone, we recommend stopping recruitment of patients who require no oxygen or simple oxygen only at the time of randomisation due to safety concerns. Follow-up of these patients should continue. However, we encourage continuing recruitment and follow-up of all those patients who, at randomisation, require either non-invasive ventilation, invasive mechanical ventilation or ECMO.*” Consequently, on 13 May 2022, recruitment to this comparison was closed for patients on no oxygen or simple oxygen only. The protocol (version 25.0 was updated accordingly.)

#### 2.5.6 *Main randomisation part F:*

In a factorial design, eligible patients (with or without influenza infection) may be randomised to the arms below. The dose listed is for adults; children <18 years old are excluded from this comparison.

- **No additional treatment**
- **Empagliflozin** 10 mg once daily for 28 days. [Introduced in protocol version 16.1; **enrolment ongoing**]

#### 2.5.7 *Main randomisation part J:*

In a factorial design, eligible patients (with or without influenza infection) may be randomised to the arms below. The dose listed is for adults; children <12 years old are excluded from this comparison.

- **No additional treatment**
- **Sotrovimab 1000 mg once** as soon as possible after randomisation. [Introduced in protocol version 21.1; **enrolment ongoing**]

#### 2.5.8 *Main randomisation part K:*

In a factorial design, eligible patients (with or without influenza infection) may be randomised to the arms below. The dose listed is for adults; children <18 years old are excluded from this comparison.

- **No additional treatment**
- **Molnupiravir 800 mg twice daily** for 5 days by mouth. [Introduced in protocol version 21.1; **enrolment ongoing**]

#### 2.5.9 *Main randomisation part L:*

In a factorial design, eligible patients (with or without influenza infection) may be randomised to the arms below. The dose listed is for adults; children <18 years old are excluded from this comparison.

- **No additional treatment**
- **Paxlovid (nirmatrelvir/ritonavir) 300/100 mg twice daily** for 5 days by mouth. [Introduced in protocol version 23.1; **enrolment ongoing**]

#### 2.5.10 *Second randomisation for adults with progressive COVID-19 (enrolment closed)*

Patients enrolled in the main RECOVERY trial and with clinical evidence of a hyper-inflammatory state may be considered for a second randomisation if they meet the following criteria:

- Randomised into the main RECOVERY trial no more than 21 days ago
- Clinical evidence of progressive COVID-19:
  - oxygen saturation <92% on room air or requiring oxygen; and
  - C-reactive protein (CRP)  $\geq 75$  mg/L
- No medical history that might, in the opinion of the attending clinician, put the patient at significant risk if they were to participate in this aspect of the RECOVERY trial

Eligible participants may be randomised between the following treatment arms:

- **No additional treatment**
- **Tocilizumab** by intravenous infusion with the dose determined by body weight. [Introduced in protocol version 4.0; **enrolment closed** 24 January 2021]

#### *Influenza Comparisons (enrolment not commenced)*

#### 2.5.11 *Main randomisation part G (enrolment not commenced):*

In a factorial design, eligible patients (with or without SARS-CoV-2 co-infection) may be randomised to the arms below. The dose listed is for adults; children <12 years old are excluded from this comparison.

- **No additional treatment**

- **Baloxavir marboxil 40mg (or 80mg if weight  $\geq$ 80kg) once daily** by mouth or nasogastric tube to be given on day 1 and day 4. [Introduced in protocol version 19.1; **enrolment not yet commenced**]

#### 2.5.12 *Main randomisation part H (enrolment not commenced):*

In a factorial design, eligible patients (with or without SARS-CoV-2 co-infection) may be randomised to the arms below.

- **No additional treatment**
- **Oseltamivir 75mg twice daily** by mouth or nasogastric tube for five days (If participant is discharged before course is complete, the participant should be provided with medication to complete the course at home. Course can be extended to 10 days for immunosuppressed patients at the managing clinician's discretion). [Introduced in protocol version 19.1; **enrolment not yet commenced**]

#### 2.5.13 *Main randomisation part I (enrolment not commenced):*

In a factorial design, eligible patients (without suspected or confirmed SARS-CoV-2 infection and with clinical evidence of hypoxia) may be randomised to the arms below.

- **No additional treatment**
- Low-dose corticosteroids: **Dexamethasone 6mg once daily given** orally or intravenously for ten days or until discharge (whichever happens earliest). [Introduced in protocol version 19.1; **enrolment not yet commenced**]

## 2.6 Definitions of outcomes

Outcomes will be assessed at 28 days after the relevant randomisation. (Analyses of 6 months are described in section 10.)

### 2.6.1 *Primary outcome*

For COVID-19 comparisons: Mortality (all-cause)

For influenza comparisons: Co-primary outcomes of Mortality (all-cause) and Time to discharge alive from hospital

### 2.6.2 *Secondary clinical outcomes*

- Time to discharge alive from hospital (for COVID-19 comparisons only)
- Use of invasive mechanical ventilation (including Extra Corporal Membrane Oxygenation [ECMO]) or death (among patients not on invasive mechanical ventilation or ECMO at time of randomisation)

### 2.6.3 *Subsidiary clinical outcomes*

- Use of ventilation (overall and by type) among patients not on ventilation (of any type) at time of randomisation

- Duration of invasive mechanical ventilation among patients on invasive mechanical ventilation at time of randomisation (defined as time to successful cessation of invasive mechanical ventilation: see section 5.1.2.2)
- Use of renal dialysis or haemofiltration (among patients not on renal dialysis or haemofiltration at time of randomisation)
- Thrombotic events (overall and by type; introduced in Protocol version 10.1)

#### 2.6.4 *Virological outcomes*

- SARS-CoV-2 RNA levels in the nasopharynx (parts J, K and L only)
- SARS-CoV-2 and influenza viral resistance markers (parts J, K and L, and parts G and H, respectively)

#### 2.6.5 *Safety outcomes*

- Cause-specific mortality (COVID-19, influenza, other infection, cardiac, stroke, other vascular, cancer, other medical, external, unknown cause)
- Major cardiac arrhythmia (recorded on follow-up forms completed from 12 May 2020 onwards)
- Major bleeding (overall and by type; introduced in Protocol version 10.1)
- Early safety of antibody-based therapy (sudden worsening in respiratory status; severe allergic reaction; temperature  $>39^{\circ}\text{C}$  or  $\geq 2^{\circ}\text{C}$  rise since randomisation; sudden hypotension; clinical haemolysis; and thrombotic events within the first 72 hours; (Main randomisation part B only)
- Non-coronavirus infection (overall and by site and putative organism [virus, bacteria, fungus, other]; introduced in Protocol version 14.0)
- Metabolic, kidney and liver complications:
  - severe hyperglycaemia: overall and by type (ketoacidosis, hyperosmolar hyperglycaemic state, hyperglycaemia requiring new use of insulin)
  - severe hypoglycaemia
  - acute kidney injury (ratio of post-randomisation peak creatinine to baseline value  $>1.5$  or new use of renal dialysis/haemofiltration; introduced in protocol V16.1)
  - liver dysfunction: peak alanine (or aspartate) transaminase and possible liver injury (defined as ALT  $>3x$  ULN plus bilirubin  $>2x$  ULN; for parts H, K and L; introduced in protocol V23.1).
- Seizures (introduced in protocol V23.1)
- Infusion reactions to sotrovimab (Main randomisation part J only; introduced in protocol V21.1)

#### 2.6.6 *Detailed derivation of outcomes*

The detailed derivation of outcomes included in statistical analysis will be described separately in a data derivation document and included in the Study Data Reviewer's Guide.

### 2.7 Hypothesis framework

For each of the primary, secondary and subsidiary outcomes, the null hypothesis will be that there is no true difference in effect between any of the treatment arms.

## 2.8 Sample size

The larger the number randomised, the more accurate the results will be, but the numbers that can be randomised will depend critically on how large the epidemic becomes. If substantial numbers are hospitalised in the participating centres then it may be possible to randomise several thousand with moderate disease and a few thousand with severe disease. Some indicative sample sizes and projected recruitment will be estimated using emerging data for several different scenarios.

The TSC will monitor recruitment and primary event rate (in active and control arms combined, i.e. blind to knowledge of the unblinded results) for ongoing comparisons. In general, the TSC will continue recruitment until such time as there are sufficient patients enrolled in the comparison to provide at least 90% power at  $2P=0.01$  to detect a clinically relevant proportional reduction (typically one-fifth) in the primary outcome.

## 2.9 Randomisation

Eligible patients will be randomised using a 24/7 secure central web-based randomisation system, developed and hosted within NDPH, University of Oxford. Users of the system will have no insight into the next allocation, given that simple randomisation is being used. If a patient is randomised inadvertently more than once during the same hospital admission, the first allocation will be used.

The implementation of the randomisation procedure will be monitored by the Senior Trials Programmer, and the TSC notified if an error in the randomisation process is identified.

### *COVID-19 treatment comparisons*

#### 2.9.1 *Main randomisation part A (enrolment closed)*

Simple randomisation will be used to allocate participants to one of the following treatment arms (in addition to usual care), which is subject to change:

- No additional treatment
- Lopinavir-Ritonavir [Introduced in protocol version 1.0; **enrolment closed** 29 June 2020]
- Corticosteroid [Introduced in protocol version 1.0; **enrolment closed to adults** 8 June 2020]
- Hydroxychloroquine [Introduced in protocol version 2.0; **enrolment closed** 5 June 2020]
- Azithromycin [Introduced in protocol version 3.0; **enrolment closed** 27 November 2020]
- Colchicine [Introduced in protocol version 11.1; **enrolment closed** 5 March 2021]
- Dimethyl fumarate [Introduced in protocol version 14.0; **enrolment closed** 19 November 2021]

The randomisation programme will allocated patients in a ratio of 2:1 between the no additional treatment arm and each of the other arms that are not contra-indicated and are

available when multiple arms were included in the protocol. Hence if all 4 active treatment arms are available, then the randomisation will be in the ratio 2:1:1:1:1. If one or more of the active drug treatments is not available at the hospital or is believed, by the attending clinician, to be contraindicated (or definitely indicated) for the specific patient, then this fact will be recorded via the web-based form prior to randomisation; random allocation will then be between the remaining arms (in a 2:1:1:1, 2:1:1 or 2:1 ratio). Since the closure of the azithromycin comparison, all comparisons in part A have used a 1:1 ratio.

### 2.9.2 *Main randomisation part B (enrolment closed)*

In a factorial design, eligible patients will be randomised simultaneously using simple randomisation with allocation ratio 1:1:1 to one of the following arms, which is subject to change:

- No additional treatment
- Convalescent plasma [Introduced in protocol version 6.0; **enrolment closed** 15 January 2021]
- Synthetic neutralising antibodies [Introduced in protocol version 9.1; **enrolment closed** 22 May 2021]

If the active treatment is not available at the hospital, the patient does not consent to receive convalescent plasma, or is believed, by the attending clinician, to be contraindicated for the specific patient, then this fact will be recorded via the web-based form and the patient will be excluded from the relevant arm in Randomisation part B.

### 2.9.3 *Main randomisation part C (enrolment closed)*

In a factorial design, eligible patients will be randomised simultaneously using simple randomisation with allocation ratio 1:1 to one of the following arms, which is subject to change:

- No additional treatment
- Aspirin [Introduced in protocol version 10.1; **enrolment closed** 21 March 2021]

### 2.9.4 *Main randomisation part D (enrolment closed)*

In a factorial design, eligible patients will be randomised simultaneously using simple randomisation with allocation ratio 1:1 to one of the following arms, which is subject to change:

- No additional treatment
- Baricitinib [Introduced in protocol version 13.0; **enrolment closed** 29 December 2021]

### 2.9.5 *Main randomisation part E (enrolment modified on advice of DMC)*

In a factorial design, eligible patients will be randomised simultaneously using simple randomisation with allocation ratio 1:1 to one of the following arms, which is subject to change:

- No additional treatment

- High-dose corticosteroids [Introduced outside UK in protocol version 13.0 and within UK in protocol version 20.0; eligibility criteria modified in protocol version 25.0; **enrolment ongoing**]

#### 2.9.6 *Main randomisation part F*

In a factorial design, eligible patients will be randomised simultaneously using simple randomisation with allocation ratio 1:1 to one of the following arms, which is subject to change:

- No additional treatment
- Empagliflozin [Introduced in protocol version 16.1; **enrolment ongoing**]

Note: From protocol version 7.0 onwards, randomisation is permitted in part B of main randomisation without randomisation in part A. From protocol version 10.1 onwards, randomisation is permitted in any combination of parts (A, B, C, etc).

#### 2.9.7 *Main randomisation part J*

In a factorial design, eligible patients will be randomised simultaneously using simple randomisation with allocation ratio 1:1 to one of the following arms:

- No additional treatment
- Sotrovimab [Introduced in protocol version 21.1; **enrolment ongoing**]

#### 2.9.8 *Main randomisation part K*

In a factorial design, eligible patients will be randomised simultaneously using simple randomisation with allocation ratio 1:1 to one of the following arms, which is subject to change:

- No additional treatment
- Molnupiravir [Introduced in protocol version 21.1; **enrolment ongoing**]

#### 2.9.9 *Main randomisation part L*

In a factorial design, eligible patients will be randomised simultaneously using simple randomisation with allocation ratio 1:1 to one of the following arms, which is subject to change:

- No additional treatment
- Paxlovid [Introduced in protocol version 23.1; **enrolment ongoing**]

#### 2.9.10 *Second randomisation for adults with progressive COVID-19 (enrolment closed)*

Eligible participants will be randomised using simple randomisation with an allocation ratio 1:1 between the following arms, which is subject to change:

- No additional treatment
- Tocilizumab [Introduced in protocol version 4.0; **enrolment closed** 24 January 2021]

## *Influenza treatment comparisons [enrolment not commenced]*

### 2.9.11 *Main randomisation part G*

In a factorial design, eligible patients will be randomised simultaneously using simple randomisation with allocation ratio 1:1 to one of the following arms:

- No additional treatment
- Baloxavir [Introduced in protocol version 19.1; **enrolment not commenced**]

### 2.9.12 *Main randomisation part H*

In a factorial design, eligible patients will be randomised simultaneously using simple randomisation with allocation ratio 1:1 to one of the following arms, which is subject to change:

- No additional treatment
- Oseltamivir [Introduced in protocol version 19.1; **enrolment not commenced**]

### 2.9.13 *Main randomisation part I*

In a factorial design, eligible patients will be randomised simultaneously using simple randomisation with allocation ratio 1:1 to one of the following arms, which is subject to change:

- No additional treatment
- Low-dose corticosteroids [Introduced in protocol version 19.1; **enrolment not commenced**]

## 2.10 Blinding

This is an open-label study. However, while the study is in progress, access to tabular results of study outcomes by treatment allocation will not be available to the research team, CIs, trial statisticians, clinical teams, or members of the TSC (unless the DMC advises otherwise). The DMC and DMC statisticians will be unblinded.

## 2.11 Data collection schedule

Baseline and 28-day outcome information will be collected on trial-specific electronic case report forms (eCRFs) and entered into a web-based IT system by a member of the hospital or research staff. Follow-up information will be collected on all study participants, irrespective of whether they complete the scheduled course of allocated study treatment. Study staff will seek follow-up information through various means, including routine healthcare systems and registries.

All randomised participants will be followed up until death or 6 months post-randomisation to the main trial (whichever is sooner). NHS Digital and equivalent organisations in the devolved nations will supply data fields relevant to trial baseline and outcome measures to NDPH, University of Oxford on a regular basis, for participants enrolled into the trial. This will be combined with the trial-specific data collected via the web-based IT system and adjudicated internally.

Longer term (up to 10 years) follow-up of UK participants only will be sought through linkage to electronic healthcare records and medical databases including those held by NHS Digital, Public Health England and equivalent bodies, and to relevant research databases (e.g. UK Biobank, Genomics England).

## 2.12 Data monitoring

During the study all study data will be supplied in strict confidence to the independent DMC for independent assessment and evaluation. The DMC will request such analyses at a frequency relevant to the emerging data from this and other studies.

The DMC has been requested to determine if, in their view, the randomised comparisons in the study have provided evidence on mortality that is strong enough (with a range of uncertainty around the results that is narrow enough) to affect national and global treatment strategies. In such a circumstance, the DMC will inform the TSC who will make the results available to the public and amend the trial arms accordingly.

The Data Monitoring Committee has determined that, in general, to consider recommending stopping a treatment early for benefit would require at least a 3 to 3.5 standard error reduction in mortality. Examinations of the data at every 10% (or even 5%) of the total data would lead to only a marginal increase in the overall type I error rate. Hence, multiple reviews by the Data Monitoring Committee have no material impact on the final analysis.

Further details about the role and membership of the independent Data Monitoring Committee are provided in the protocol.

## 2.13 Trial reporting

The trial will be reported according to the principles of the CONSORT statements.<sup>2, 3, 4</sup> The exact composition of the trial publication(s) depends on the size of the epidemic, the availability of drugs, and the findings from the various pairwise comparative analyses (with the no additional treatment arm) in the main trial.

# 3 ANALYSIS POPULATIONS

## 3.1 Population definitions

The intention to treat (ITT) population will be all participants randomised, irrespective of treatment received. This ITT population will be used for analysis of efficacy and safety data. For interim analyses, baseline data will be reported for all participants with data available and outcome data will be reported for all participants who have died, been discharged from hospital, or reached day 28 after the first randomisation.

## 4 DESCRIPTIVE ANALYSES

### 4.1 Participant throughput

The flow of participants through the trial will be summarised for each separate pairwise comparison using a CONSORT diagram. The flow diagram will show the contribution of participants from each of the paths (from each of the parts of the main randomisation and from the second randomisation), where applicable. The flow diagrams will describe the numbers of participants randomly allocated, who received allocation, withdrew consent, and included in the ITT analysis population. The flow diagrams for arms in the main randomisation will also report the number of participants who underwent the second randomisation (where applicable).

### 4.2 Baseline comparability of randomised groups

The following characteristics will be described separately for patients randomised to each main comparison (for each separate pairwise comparison of active treatment with the no additional treatment arm), and separately for the first and second randomisation.

#### *COVID-19 treatment comparisons*

##### 4.2.1 Main randomisation – COVID-19 comparisons (parts A, B, C, D, E, F, J, K, L)

- Age at randomisation
- Sex
- Ethnicity
- Region (UK, non-UK)
- Time since symptom onset
- Time since hospitalisation
- Current respiratory support (none, oxygen only, non-invasive ventilation, invasive mechanical ventilation [including ECMO])
- Comorbidities (diabetes, heart disease, chronic lung disease, tuberculosis, human immunodeficiency virus, severe liver disease, severe kidney impairment)
- SARS-CoV-2 test result
- If female, known to be pregnant
- Use of systemic corticosteroid (including those allocated to corticosteroid in parts A or I)
- Use of other relevant treatments (e.g. remdesivir, interleukin-6 antagonist, monoclonal anti-SARS-CoV-2 neutralising antibody, baricitinib, molnupiravir, paxlovid)
- Prior SARS-CoV-2 vaccination
- For parts B, J, K and L only, serum anti-SARS-CoV-2 antibody status (anti-S and anti-N)
- For parts J, K and L only, serum SARS-CoV-2 antigen concentration
- For parts J, K and L only, nasal/oropharyngeal SARS-CoV-2 RNA level
- Laboratory markers (introduced in protocol v9.1):
  - C-reactive protein
  - Estimated glomerular filtration rate (calculated using the CKD-EPI formula)
  - D-dimer

#### 4.2.2 *Second randomisation*

In addition to the above:

- Current respiratory support
- Latest oxygen saturation measurement
- Latest C-reactive protein
- Latest ferritin
- Latest estimated glomerular filtration rate (calculated using the CKD-EPI formula)
- Allocation in main randomisation parts A, B, C, D and E
- Interval between first and second randomisation

The number and percentage will be presented for binary and categorical variables. The mean and standard deviation or the median and the interquartile range will be presented for continuous variables.

### *Influenza treatment comparisons*

#### 4.2.3 *Main randomisation – influenza comparisons (parts G, H, I)*

- Age at randomisation
- Sex
- Ethnicity
- Region (UK, non-UK)
- Time since symptoms onset
- Time since hospitalisation
- Current respiratory support (none, oxygen only, non-invasive ventilation, invasive mechanical ventilation [including ECMO])
- Comorbidities (diabetes, heart disease, chronic lung disease, tuberculosis, human immunodeficiency virus, severe liver disease, severe kidney impairment)
- Influenza test result
- If female, known to be pregnant
- Use of systemic corticosteroid (including those allocated to corticosteroid in part I)
- Use of other relevant treatments (e.g. oseltamivir, baloxavir)
- Prior influenza vaccination (within the past 12 months)
- Laboratory markers:
  - C-reactive protein
  - Estimated glomerular filtration rate (calculated using the CKD-EPI formula)
  - D-dimer

### 4.3 *Completeness of follow-up*

All reasonable efforts will be taken to minimise loss to follow-up, which is expected to be minimal as data collection for primary and secondary outcomes using trial-specific eCRFs is combined with linkage to routine clinical data on study outcomes from NHS Digital, ICNARC, and similar organisations in the devolved nations.

The number and percentage of participants with follow-up information at day 28 after the relevant randomisation will be reported. Data will be shown for each of the following: all-

cause mortality, hospital discharge status, ventilation status, and will be shown for each randomised group for the main and second randomisation separately.

#### 4.4 Adherence to treatment

The number and proportion of patients who did not receive the treatment they were allocated to will be reported. If any other trial treatment options were known to be received, instead of or in addition to, the allocated treatment during the 28-day follow-up period after the first randomisation, these will be collected and reported. Details on the number of days (or doses) of treatment received will be reported for all trial treatments received where available.

### 5 COMPARATIVE ANALYSES AT 28 DAYS

For all outcomes, the primary analysis will be performed on the intention to treat (ITT) population at 28 days after randomisation. (Additional details specific to the comparison of REGEN-COV2 vs. usual care [part B] are provided in Appendix I and for the comparison of sotrovimab vs. usual care [part J], molnupiravir vs. usual care [part K], and paxlovid vs. usual care [part L] are provided in Appendix II.)

Pairwise comparisons will be made between each treatment arm and the no additional treatment arm (reference group) in that particular randomisation (main randomisation part A, main randomisation part B, main randomisation part C, etc.). Since not all treatments may be available or suitable for all patients, those in the no additional treatment arm will only be included in a given comparison if, at the point of their randomisation, they *could* alternatively have been randomised to the active treatment of interest (i.e. the active treatment was available at the time and it was not contra-indicated). The same applies to treatment arms added at a later stage; they will only be compared to those patients recruited concurrently.

#### 5.1 Main randomisation (all parts)

In each component of the factorial design, the main effects of treatments evaluated in a particular part will be presented and tested across all arms in the other main randomisation parts combined, as described in this section. (Assessments of whether the effects of treatments in the part in question vary depending on other randomised treatments are described in section 5.6).

##### 5.1.1 Primary and secondary outcome

###### 5.1.1.1 Mortality

Mortality (all-cause) will be summarised with counts and percentages by randomised comparison group. A time-to-event analysis will be conducted using Cox proportional hazards regression, adjusted for baseline characteristics as described in Section 5.4, to estimate the hazard ratio, 95% confidence interval and corresponding p-value for each treatment group versus the no additional treatment group. Kaplan-Meier estimates for the time to event will also be plotted. For the primary outcome, discharge alive before the relevant time period (28

days after randomisation) will be assumed as absence of the event (unless there is additional data confirming otherwise).

#### *5.1.1.2 Time to discharge alive from hospital*

A time-to-event analysis will be used to compare each treatment group with the no additional treatment group. As described for the primary outcome, the adjusted hazard ratio and its confidence interval will be estimated using Cox proportional hazards regression, adjusted for baseline characteristics as described in Section 5.4, to estimate the hazard ratio, 95% confidence interval and corresponding p-value for each treatment group versus the no additional treatment group. Kaplan-Meier curves will be drawn. Patients who die in hospital will be censored after 28 days after randomisation. This gives an unbiased estimate of the recovery rate and comparable estimates to the competing risks approach in the absence of other censoring (which is expected to be very minimal).<sup>5</sup>

#### *5.1.1.3 Use of invasive mechanical ventilation (including ECMO) or death*

Counts and percentages will be presented by randomised group and a log-binomial regression model, adjusted for baseline characteristics as described in Section 5.4, will be used to estimate the risk ratio, confidence interval and p-value for each pairwise comparison with the no additional treatment arm. Each component of this composite outcome will also be summarised. Patients who were already on invasive mechanical ventilation or ECMO at randomisation will be excluded from these analyses.

### *5.1.2 Subsidiary clinical outcomes*

#### *5.1.2.1 Use of ventilation (overall and by type)*

Counts and percentages will be presented by randomised group for patients who received any assisted ventilation, together with adjusted risk ratios and confidence intervals for each pairwise comparison with the no additional treatment arm estimated using log-binomial regression, as described above. The number of patients receiving the two main types of ventilation will also be reported: non-invasive ventilation (including CPAP, other non-invasive ventilation or high-flow nasal oxygen), and invasive mechanical ventilation (including ECMO). Patients who were already receiving ventilation<sup>a</sup> at randomisation will be excluded from these analyses.

#### *5.1.2.2 Duration of invasive mechanical ventilation (time to successful cessation of invasive mechanical ventilation)*

Successful cessation of invasive mechanical ventilation will be defined as removal of invasive mechanical ventilation within (and survival to) 28 days after randomisation. A time-to-event analysis will be used to compare each treatment group with the no additional treatment group using Cox proportional hazards regression to estimate the hazard ratio and its confidence interval, as described above. Kaplan-Meier curves will be drawn. Patients who die within 28 days of randomisation will be censored *after* 28 days after randomisation. Patients

---

<sup>a</sup> Participants recruited to the main randomisation prior to protocol version 9.1 who were already receiving oxygen at randomisation will also be excluded from these analyses (since it is not possible to distinguish those who were already receiving non-invasive ventilation).

who were not already on invasive mechanical ventilation or ECMO at randomisation will be excluded from these analyses.

#### *5.1.2.3 Use of renal dialysis or haemofiltration*

Counts and percentages will be presented by randomised group and the adjusted risk ratio will be calculated for each pairwise comparison with the no additional treatment arm using log-binomial regression, with confidence intervals and p-values reported. Patients who were already on renal dialysis or haemofiltration at randomisation will be excluded from these analyses.

#### *5.1.2.4 Thrombotic event*

Counts and percentages will be presented by randomised group. The absolute risk differences (and associated confidence intervals) will also be estimated by applying the adjusted risk ratio (or its 95% upper and lower limits) to the risk in the no additional treatment arm and then calculating the absolute difference between these values and the risk seen in the no additional treatment arm. Type of thrombotic event will also be described: (i) acute pulmonary embolism; (ii) deep vein thrombosis; (iii) ischaemic stroke, (iv) myocardial infarction; (v) systemic arterial embolism; and (vi) all sites combined.

### *5.1.3 Virological outcomes*

#### *5.1.3.1 SARS-CoV-2 RNA levels in the nasopharynx*

For parts J, K and L only: Geometric mean and standard error SARS-CoV-2 levels will be presented at days 3 and 5. Comparisons will be made between treatment groups. Estimates will be obtained from analysis of covariance (ANCOVA) using the log transformed values after adjustment for each participant's baseline value and the baseline characteristics as described in section 5.4. Missing values will be imputed using procedures set out for continuous outcomes in section 9.3.2.5.

#### *5.1.3.2 SARS-CoV-2 and influenza viral resistance markers*

Counts and percentages of SARS-CoV-2 (for parts J, K and L) and influenza (for parts H and I) viral resistance markers will be presented by randomised group.

## *5.2 Second randomisation*

Evaluation of treatment effects in the main randomisation and the second randomisation will be conducted independently, as described in 5.1.

## *5.3 Pre-specified subgroup analyses*

Pre-specified subgroup analyses will be conducted for each part of the main randomisation and for the second randomisation, for the following outcomes:

- Mortality (all-cause)
- Time to discharge from hospital
- Use of invasive mechanical ventilation (including ECMO) or death

Tests for heterogeneity (or tests for trend for 3 or more ordered groups) will be conducted to assess whether there is any good evidence that the effects in particular subgroups differ materially from the overall effect seen in all patients combined. Results will be presented on forest plots as hazard ratios, or risk ratios, with confidence intervals. The following subgroups will be examined based on information at randomisation:

- Age (<70; 70-79; 80+ years)
- Sex (Male; Female)
- Ethnicity (White; Black, Asian or Minority Ethnic)
- Region (UK, non-UK)
- Time since illness onset ( $\leq 7$  days;  $> 7$  days)
- Requirement for respiratory support
  - For main randomisation: None; Oxygen only; Non-invasive ventilation; Invasive mechanical ventilation (including ECMO)<sup>b</sup>
  - For second randomisation: No ventilator support (including no or low-flow oxygen); Non-invasive ventilation (including CPAP, other non-invasive ventilation, or high-flow nasal oxygen), Invasive mechanical ventilation (including ECMO)
- Use of systemic corticosteroid (including dexamethasone)
- Concomitant viral infection:
  - For parts J, K and L: presence or absence of confirmed influenza infection
  - For parts G and H: presence or absence of confirmed SARS-CoV-2 infection
- For part B only: Recipient anti-SARS-CoV-2 anti-S antibody status at randomisation (negative, positive as defined by the assay manufacturer, Roche). (This is the key subgroup for the REGEN-COV2 comparison; see Appendix I.)
- For parts J, K and L only: Recipient anti-SARS-CoV-2 anti-N antibody concentration at randomisation (negative; positive) as defined by the assay manufacturer, Roche). (This may be the key subgroup for the sotrovimab comparison; see Appendix II.)
- For parts J, K and L only: Serum SARS-CoV-2 antigen level ( $<$  and  $\geq$  median) at randomization.

#### 5.4 Adjustment for baseline characteristics

The main analyses described above will be adjusted for age and requirement for respiratory support at baseline (using categories defined in section 4.2). Adjustment for these two major predictors of mortality is desirable because it provides a safeguard against the impact that any chance imbalances in their frequencies between randomised groups may have on the randomised comparisons, whilst also leading to a small expected increase in statistical power. Analyses with *further* adjustment for other pre-specified subgroups (see section 4.2) will also be done and presented as sensitivity analyses.

#### 5.5 Sensitivity analyses

For parts A to L only, sensitivity analyses of the primary and secondary outcomes will be conducted among those patients with a positive test for SARS-COV-2 (i.e. confirmed cases).

---

<sup>b</sup> Participants recruited before protocol V9.1 who were receiving oxygen would be presented in a fifth subgroup but not included in the test for trend

Sensitivity analyses of the primary and secondary outcomes will be conducted (a) without adjustment for characteristics at randomisation and (b) with adjustment for all key baseline pre-specified subgroups (see section 5.4).

## 5.6 Other exploratory analyses

In addition, for each randomised assessment, exploratory analyses will be conducted to test for interactions with other treatments allocated in each of the different randomisations, provided that doing so does not lead to premature unblinding of results for ongoing comparators.

Non-randomised exploratory analyses will be used to explore the likely influence of different levels of convalescent plasma antibody concentrations on the efficacy of convalescent plasma.

Additional analyses will set the results for children (<18 years) and pregnant women in the context of the overall results.

## 5.7 Significance levels and adjustment of p-values for multiplicity

Evaluation of the primary trial (main randomisation) and secondary randomisation will be conducted independently, and no adjustment be made for these. Formal adjustment will not be made for multiple treatment comparisons, the testing of secondary and subsidiary outcomes, or subgroup analyses (with one exception; see Appendix I). However, due allowance for multiple testing will be made in the interpretation of the results: the larger the number of events on which a comparison is based and the more extreme the P-value after any allowance has been made for the nature of the particular comparison (i.e. primary or secondary; pre-specified or exploratory), the more reliable the comparison and, hence, the more definite any finding will be considered. 95% confidence intervals will be presented for the main comparisons.

For each of the influenza comparisons (parts G, H, and I), Holm's procedure will be used to control the family-wise error rate across the two co-primary outcomes at 5%.<sup>7</sup>

## 5.8 Statistical software employed

The statistical software SAS version 9.4 and R Studio 3.6.2 (or later) for Windows will be used for the interim and final analyses.

## 5.9 Data standards and coding terminology

Datasets for analysis will be prepared using CDISC standards for SDTM and ADaM. Wherever possible, clinical outcomes (which may be obtained in a variety of standards, including ICD10 and OPCS-4) will be coded using MedDRA version 20.1.

# 6 SAFETY DATA

Suspected serious adverse reactions (SSARs) and suspected unexpected serious adverse reactions (SUSARs) will be listed by trial allocation.

For each of the following, counts and percentages will be presented by randomised group. Where possible, the absolute risk differences will also be presented with confidence intervals (estimated using the methods described in section 5.1.2.4).

### 6.1 Cause-specific mortality

Cause-specific mortality (COVID-19, other infection, cardiac, stroke, other vascular, cancer, other medical, external, unknown cause) will be analysed in a similar manner to the primary outcome.

### 6.2 Major cardiac arrhythmia

Type of arrhythmia will also be described: (i) atrial flutter or fibrillation; (ii) supraventricular tachycardia; (iii) ventricular tachycardia; (iv) ventricular fibrillation; (v) atrioventricular block requiring intervention, with subtotals for (i)-(ii) and (iii)-(iv).

### 6.3 Major bleeding

Type of bleeding will also be described: (i) intracranial bleeding; (ii) gastro-intestinal bleeding; (iii) other bleeding site, and (iv) all sites combined.

### 6.4 Early safety of anti-coronavirus antibody-based therapy

Additional safety data will be collected in a subset of patients randomised to part B: (i) sudden worsening in respiratory status; (ii) severe allergic reaction; (iii) temperature  $>39^{\circ}\text{C}$  or  $\geq 2^{\circ}\text{C}$  rise since randomisation; (iv) sudden hypotension; (v) clinical haemolysis; and (vi) thrombotic event.

### 6.5 Other infections

Other infections occurring after randomisation will be described. These will be classified primarily by site (pneumonia, urinary tract, biliary, other intra-abdominal, blood stream, skin, other). Information on putative organism (other virus, bacterial, fungal, other and unknown) is also collected.

### 6.6 Metabolic, kidney and liver complications

Incidence of the following metabolic and biochemical complications after randomisation will be described:

- Severe hyperglycaemia (separately and overall; introduced 28 Jul 2021):
  - Ketoacidosis (defined as combination of ketosis [blood ketones  $\geq 1.5$  mmol/L or urine ketones  $\geq 2+$ ] and acidosis [venous bicarbonate  $< 15$  mmol/L])
  - Hyperglycaemic hyperosmolar state (defined as glucose  $> 33$  mmol/L and calculated osmolality  $> 320$  mOsm/L)
  - Other hyperglycaemia requiring new use of insulin
- Severe hypoglycaemia (causing reduced conscious level requiring another person to help recover; introduced 28 Jul 2021)

- Acute kidney injury (defined as ratio of post-randomisation peak creatinine to baseline value  $>1.5x$  or new use of renal dialysis/haemofiltration; introduced 28 Jul 2021):
- Liver dysfunction (for parts K and L and part G; introduced 28 Mar 2022):
  - Peak alanine (or aspartate) transaminase in the following categories ( $<3 \times$  upper limit of normal [ULN];  $\geq 3 < 5x$  ULN;  $\geq 5x$  ULN)
  - Peak bilirubin ( $\leq 2x$  ULN;  $>2x$  ULN)
  - Possible liver injury (defined as ALT  $>3x$  ULN plus bilirubin  $>2x$  ULN)

## 6.7 Seizures

The incidence of seizures (introduced on 28 Mar 2022)

## 6.8 Infusion reactions to sotrovimab

For part J, the frequency and percentage of infusion reactions to sotrovimab will be described (overall and by severity)

## 7 ADDITIONAL POST-HOC EXPLORATORY ANALYSIS

Any post-hoc analysis requested by the oversight committees, a journal editor or referees will be labelled explicitly as such. Any further future analyses not specified in the analysis protocol will be exploratory in nature and will be documented in a separate statistical analysis plan.

## 8 DIFFERENCES FROM PROTOCOL

The testing of multiple treatment arms will not formally be adjusted for, but given the number of comparisons, due allowance will be made in their interpretation. Formal methods of adjustment for multiplicity were not adopted because of treatment arms being added over time (including the factorial convalescent plasma comparison), unequal recruitment into each arm, and the ultimate number of treatments under evaluation not being known in advance.

## 9 EARLY PHASE ASSESSMENTS

The following approach is required for the evaluation of treatments indicated as undergoing Early Phase Assessment in the protocol (introduced in Protocol version 14.0):

### 9.1 Definitions of clinical outcomes

#### 9.1.1 *Primary outcome*

- WHO ordinal scale on day 5

#### 9.1.2 *Secondary clinical outcomes*

- Time to sustained improvement (i.e., value better than baseline value persisting for >1 day) by at least one category on the WHO ordinal scale from baseline
- S/F<sub>94</sub> ratio at day 5
- Time to discharge from hospital
- Improvement in clinical status at day 10
- Blood C-reactive protein at day 5

#### 9.1.3 *Subsidiary clinical outcomes*

- All other subsidiary outcomes as described above (section 2.6.3)

#### 9.1.4 *Safety outcomes*

- Flushing (incidence, severity)
- Gastrointestinal symptoms (incidence, severity)
- Reasons for stopping study treatment
- Transaminitis (ALT >3x upper limit of normal)
- Acute kidney injury (creatinine >1.5x value entered at randomisation)
- All other subsidiary outcomes as described above (section 2.6.5)

### 9.2 Baseline comparability of randomised groups

Unless otherwise specified, analyses will follow the plan described above (section 4). In addition, the following characteristics will be described:

- Oxygen saturation measurement on air (if available)
- S/F<sub>94</sub> ratio
- WHO Ordinal Scale
- All other characteristics as described above (section 4.2)

### 9.3 Comparative analysis

Unless otherwise specified, comparative analyses will follow the plan described above (section 5). In addition,

#### 9.3.1 *Primary outcome*

The primary comparison will involve an “intention to treat” analysis among all participants randomised between the active arm and its control of the effect of the active treatment on WHO scale at day 5, adjusted for baseline score. A proportional odds model will be used to assess the common odds ratio of better outcome for each pairwise comparison with the no additional treatment arm.<sup>8</sup> In addition, a sensitivity analysis to the proportional odds model using Howard’s method will be performed if the proportional odds assumption is not satisfied.<sup>9</sup>

### 9.3.2 *Secondary outcomes*

#### 9.3.2.1 *Time to sustained improvement by at least one category on the WHO ordinal scale from baseline*

A time-to-event analysis will be used to compare each treatment group with the no additional treatment group using the log-rank test (restricted to the first 10 days of the trial as the WHO score is not collected after this). The rate ratio and its confidence interval will be estimated from the log-rank observed minus expected statistic and its variance, and Kaplan-Meier curves will be drawn.

#### 9.3.2.2 *Improvement in clinical status at day 10*

Counts and percentages will be presented by randomised group for patients with an improvement of at least one category on the WHO ordinal scale from baseline, together with odds ratios and confidence intervals for each pairwise comparison with the no additional treatment arm.

#### 9.3.2.3 *Blood C-reactive protein at day 5*

Geometric mean C-reactive protein at day 5 will be compared between treatment arms. Estimates will be obtained from analysis of covariance (ANCOVA) for the log transformed CRP values after adjustment for each participant's baseline value. Approximate standard errors for the geometric means will be calculated from the confidence intervals. Missing CRP values will be handled as described in section 9.3.2.5.

#### 9.3.2.4 *S/F<sub>94</sub> ratio at day 5*

Mean S/F<sub>94</sub> ratio at day 5 will be compared between treatment arms. Estimates will be obtained from analysis of covariance (ANCOVA) after adjustment for each participant's baseline S/F<sub>94</sub> ratio. Missing S/F<sub>94</sub> ratio values will be handled as described in section 9.3.2.5

#### 9.3.2.5 *Imputation of missing data*

All analyses will be done according to the intention-to-treat principle and, hence, missing secondary outcome data will be imputed. For each of the continuous outcomes (e.g., CRP, S/F<sub>94</sub> ratio) missing post-randomisation results will be imputed using multiple imputation, using 20 imputed data sets, with results across imputations being combined using the methods of Rubin.<sup>10</sup> The imputation procedure will take into consideration each participant's key baseline characteristics (listed in section 5.8), treatment allocation and any intermediate follow-up values of the biomarker, where available. For S/F<sub>94</sub> ratio, WHO ordinal scale values on days 3 and 5 will also be used in the imputation procedure. For patients who are discharged from hospital and for whom it is not possible to measure S/F<sub>94</sub> ratio at day 5, a value of 4.76<sup>c</sup> will be imputed. The results from these analyses will be compared with those from equivalent "complete-case" analyses, but primary emphasis will be placed on the results after multiple imputation. All multiple imputation analyses will be implemented using the multiple imputation procedure in SAS version 9.4 (SAS Institute, Cary NC), using the expectation-maximization algorithm (which assumes a multivariate normal distribution) to impute values.

---

<sup>c</sup> 4.76 = 1.0/0.21 (ie, the value of healthy lungs which provide 100% saturations when breathing 21% oxygen)

For any continuous variables with missing baseline values, the mean among those with observed values will be imputed.

### 9.3.3 *Safety outcomes*

Counts and percentages will be presented by randomised group. The absolute risk differences will also be presented with confidence intervals for each of the following:

- Flushing (incidence, severity)
- Gastrointestinal symptoms (incidence, severity)
- Reasons for stopping study treatment
- Transaminitis (ALT >3x upper limit of normal)
- Acute kidney injury (creatinine >1.5x value entered at randomisation)

## 10 6-MONTH AND LONGER-TERM ASSESSMENTS

This section details the proposed analysis of the clinical outcomes 6 months after initial randomisation in the RECOVERY trial (for all participants). A similar approach will be used for analyses of longer-term outcomes for UK participants only.

### 10.1 Objectives

The **primary objective** of these analyses is to provide reliable estimates of study treatments on all-cause mortality within 6 months of the relevant randomisation.

The **key safety objectives** are to provide reliable estimates of these on non-COVID infections and non-COVID causes of death.

### 10.2 Comparative analyses at 6 months

The primary analyses will be performed on the ITT population at 6 months. Pairwise comparisons will be made between each treatment arm and the no additional treatment arm (reference group) in that particular randomisation using the same approach described for the 28 day analyses (see section 5).

#### 10.2.1 *Primary outcome*

The primary outcome is **6-month mortality** (all-cause). This will be summarised with counts and percentages by randomised comparison group. A time-to-event analysis will be conducted using the approach described for the 28-day analyses (see section 5.1.1.1). Results will be interpreted in the context of the results of analyses at 28 days.

For the analysis of REGEN-COV2, the primary outcome will first be assessed among those participants who are known to be seronegative (anti-S SARS-CoV-2 antibody negative) at randomisation (see Appendix I).

For the analysis of sotrovimab, the primary analysis population is yet to be determined, but will be specified before any unblinded analyses are conducted (except for the independent Data Monitoring Committee) (see Appendix II).

#### 10.2.2 *Pre-specified subgroup analyses*

Subgroup analyses will be conducted for 6-month mortality (all-cause) using methods described in section 5.3. The following subgroups will be examined based on information at randomisation:

- For dexamethasone comparisons: Requirement for respiratory support (with test for trend)
- For tocilizumab comparison: Use of systemic corticosteroid (including dexamethasone) (with test for heterogeneity)
- For REGEN-COV2 comparison: Recipient anti-SARS-CoV-2 anti-S antibody concentration (positive, negative, unknown; with test for heterogeneity between seronegative and seropositive participants)

- For baricitinib comparison: use of systemic corticosteroid (including dexamethasone) and, separately, use of interleukin-6 antagonist (e.g. tocilizumab, sarilumab) (each with test for heterogeneity)
- For sotrovimab comparison: Recipient anti-SARS-CoV-2 anti-N antibody concentration (positive, negative, unknown; with test for heterogeneity between seronegative and seropositive participants) and SARS-CoV-2 antigen level (< or ≥ median)
- For high-dose dexamethasone comparison: Requirement for respiratory support (with test for trend)

Other subgroup analyses (see section 5.3) may be conducted but will be considered exploratory in nature.

#### 10.2.3 *Adjustment for baseline characteristics*

The main analyses will be adjusted for age and level of respiratory support at baseline (and potentially for other important imbalances) using the approach described in section 5.1.1.1.

#### 10.2.4 *Sensitivity analyses*

Sensitivity analyses of the primary outcome will be conducted with adjustment for all key baseline pre-specified subgroups (see section 5.4).

#### 10.2.5 *Significance levels and adjustment of p-values for multiplicity*

This will take the same approach as described for 28-day analyses (see section 5.7)

### 10.3 Safety data

The key safety outcome is **major non-COVID infection** (associated with hospitalisation or death). These will be presented overall, and by site (e.g. pneumonia, urinary tract, biliary, other intra-abdominal, bloodstream, skin, other) and, where possible, by putative organism (e.g. virus, bacteria, fungus, other). Counts and percentages will be presented by randomised group. Where possible, the absolute risk differences will also be presented with confidence intervals.

### 10.4 Other exploratory analyses

Secondary, subsidiary clinical and other safety outcomes (as specified earlier in this document) may be assessed in exploratory analyses. In addition, hospital recorded diagnoses (see Definition and Derivation of Baseline Characteristics and Outcomes SOP section 8.1.2) may be explored to assess other long-term effects of study treatments.

The selection and interpretation of these additional analyses will be informed by the 28-day results and what is known about the potential longer term impacts of the study treatments (particularly with respect to known hazards of treatment).

### 10.5 Censoring and analysis

For the 6 month analyses, participants will be censored at the earliest of death, withdrawal of consent, known exit from the NHS,<sup>d</sup> or on study day 184 (where day of randomisation is study day 1). For later analyses, a similar censoring approach will be used (e.g. day 731 for a 2 year analysis).

---

<sup>d</sup> NHS Digital (and equivalent organisations in the devolved nations) are notified if patients are no longer receiving NHS care (typically due to emigration).

## 11 REFERENCES

### 11.1 Trial documents

Study protocol, case report forms, training materials, and statistical analysis plan are published on the trial website.

### 11.2 Other references

1. Gamble C, Krishan A, Stocken D, Lewis S, Juszcak E, Doré C, Williamson PR, Altman DG, Montgomery A, Lim P, Berlin J, Senn S, Day S, Barbachano Y, Loder E. Guidelines for the Content of Statistical Analysis Plans in Clinical Trials. *JAMA* 2017;318(23):2337-2343.
2. Schulz KF, Altman DG, Moher D for the CONSORT Group. CONSORT 2010 Statement: updated guidelines for reporting parallel group randomised trials. *BMJ* 2010;340:698-702.
3. Juszcak E, Altman DG, Hopewell S, Schulz KF. Reporting of multi-arm parallel-group randomized trials: extension of the CONSORT 2010 statement. *JAMA* 2019;321(16):1610-1620.
4. Dimairo M, Pallmann P, Wason J, Todd S, Jaki T, Julious SA, Mander AP, Weir CJ, Koenig F, Walton MK, Nicholl JP, Coates E, Biggs K, Hamasaki T, Proschan MA, Scott JA, Ando Y, Hind D, Altman DG; ACE Consensus Group. The Adaptive designs CONSORT Extension (ACE) statement: a checklist with explanation and elaboration guideline for reporting randomised trials that use an adaptive design. *BMJ*. 2020 Jun 17;369:m115. doi: 10.1136/bmj.m115. PMID: 32554564; PMCID: PMC7298567.
5. Betensky RA and Schoenfeld DA. Nonparametric Estimation in a Cure Model with Random Cure Times. *Biometrics* 2001;57:282-286.
6. The National SARS-CoV-2 Serology Assay Evaluation Group. Performance characteristics of five immunoassays for SARS-CoV-2: a head-to-head benchmark comparison. *Lancet Infect Dis* 2020; 20: 1390-1400
7. Holm S. A Simple Sequentially Rejective Multiple Test Procedure. *Scandinavian Journal of Statistics* 1979;6:65-70.9.
8. McCullagh P. Regression models for ordinal data. *J R Statist Soc B*. 1980; 42: 109-42
9. Howard G, Waller JL, Voeks JH, Howard VJ, Jauch EC, Lees KR, et al. A simple, assumption-free, and clinically interpretable approach for analysis of modified Rankin outcomes. *Stroke*. 2012;43:664–669
10. Rubin D. Multiple imputation for non-response in surveys. New York: John Wiley; 1987.

## 12 APPENDIX I: ANALYSES OF REGEN-COV2

### 12.1 Background & rationale

The RECOVERY trial is testing multiple interventions in a broad population of patients hospitalised with COVID-19. The protocol and statistical analysis plan outline the methods that are to be used in the analysis of these interventions and, to date, the same approach has been appropriate for all completed comparisons. However, it is important that the statistical analysis plan be informed by the best available information about the treatment being tested<sup>1</sup> and the pathophysiology of the disease.

Relevant new information about the effects of REGEN-COV2 have emerged since it was added to the trial in September 2020.

REGEN-COV2 is a mixture of two synthetic monoclonal antibodies which bind to the receptor binding domain of the SARS-CoV-2 spike protein and neutralise the virus.<sup>2</sup> Recently-published trials of REGEN-COV2 in ambulatory patients (i.e. those recently diagnosed in the community) have demonstrated that it has larger effects on viral load among people who are “seronegative” at the time of randomisation (i.e. they do not have detectable antibodies of their own against SARS-CoV-2), and seropositive patients derive little or no benefit (in terms of reduction in viral load) from REGEN-COV2, compared to placebo.<sup>3</sup> Participant serostatus therefore is a potentially key modifier of the effect of REGEN-COV2 that may be observed in RECOVERY.

All participants entering the REGEN-COV2 comparison in RECOVERY are asked to provide a serum sample which is sent to a central laboratory at the University of Oxford, where antibodies against SARS-CoV-2 are measured using a validated assay. Previous assessments of this assay alongside commercially available assays shows excellent performance at discriminating prior SARS-CoV-2 infection with sensitivity and specificity above 98%.<sup>4</sup>

Earlier versions of the statistical analysis plan recognised the importance of the seronegative subgroup, but review of the emerging literature and regulatory guidance<sup>5</sup> has led to a change in approach to these analyses. The revised analysis plan for the REGEN-COV2 comparison explicitly tests the hypothesis that any benefit of REGEN-COV2 on the primary outcome may be wholly or largely restricted to patients who are seronegative at the time of randomisation with little or no benefit among those who are seropositive at that point.

For the avoidance of doubt, all decisions about this modification to the analytical plan were made before recruitment was complete and before any members of the trial steering committee (who are responsible for drafting and approving the SAP) or investigators had access to any unblinded analyses of clinical outcome data for the REGEN-COV2 comparison. No members of the independent Data Monitoring Committee (who are the only individuals who can review interim unblinded analyses) were involved in this change.

### 12.2 Analytical plan

The primary outcome and secondary outcomes remain unchanged. For each outcome, rate ratios and 95% confidence intervals will be calculated separately for participants who are

seronegative, seropositive, or with unknown status as well as for the whole trial population. A test for heterogeneity between seronegative and seropositive participants will be presented. The results will be interpreted based on the totality of the evidence.

For the purposes of any regulatory submission: Because any beneficial effect of REGEN-COV2 is hypothesised to be larger among seronegative participants (and may be negligible in seropositive participants), the primary outcome will first be assessed among participants who are known to be seronegative at randomisation. If the null hypothesis is rejected in the seronegative group at 2-tailed  $p=0.05$ , then the primary outcome will be assessed among the whole population (i.e. seronegative, seropositive, and those with unknown status combined). Otherwise, no further hypothesis testing will be performed.

A similar approach will be taken for each of the two pre-specified secondary outcomes (discharge alive within 28 days and, among patients not on invasive mechanical ventilation at baseline, the use of invasive mechanical ventilation or death) if both primary hypotheses are rejected. Hypothesis testing will first be conducted among the participants who are known to be seronegative at randomisation and, if the null hypothesis is rejected at 2-tailed  $p=0.025$ , then will be assessed among the whole population (see Table).

**Table: Hierarchical Testing Order**

Hierarchy Number	Type of Outcome	Outcome	Analysis Population	Significance level, $\alpha$ (2-sided)
1.	Primary	Mortality (all-cause), 28 days after randomisation	Seronegative at randomisation	0.05
2.	Primary	Mortality (all-cause), 28 days after randomisation	All participants randomised	0.05
3.*	Secondary	Time to discharge alive from hospital, within 28 days after randomisation	Seronegative at randomisation	0.025
4.	Secondary	Time to discharge alive from hospital, within 28 days after randomisation	All participants randomised	0.025
3.*	Secondary	Use of invasive mechanical ventilation (including ECMO) or death	Seronegative and not on invasive mechanical ventilation at randomisation	0.025
4.	Secondary	Use of invasive mechanical ventilation (including ECMO) or death	All participants randomised not on invasive mechanical ventilation at randomisation	0.025

\* These will be performed simultaneously. Testing will only proceed to the respective overall population if the null hypothesis is rejected in the seronegative group at the specified level of statistical significance.

## 12.3 References

1. Food and Drug Administration. E9 Statistical Principles for Clinical Trials. 1998.

2. Hansen J, Baum A, Pascal KE, et al. Studies in humanized mice and convalescent humans yield a SARS-CoV-2 antibody cocktail. *Science* 2020;369:1010-4.
3. Weinreich DM, Sivapalasingam S, Norton T, et al. REGN-COV2, a Neutralizing Antibody Cocktail, in Outpatients with Covid-19. *N Engl J Med* 2021;384:238-51.
4. National S-C-SAEG. Performance characteristics of five immunoassays for SARS-CoV-2: a head-to-head benchmark comparison. *Lancet Infect Dis* 2020;20:1390-400.
5. Food and Drug Administration. Enrichment strategies for clinical trials to support determination of effectiveness of human drugs and biological products - guidance for industry. 2019.

## 13 APPENDIX II: ANALYSES OF SOTROVIMAB AND OTHER ANTI-VIRALS FOR COVID-19

### 13.1 Background & rationale

The RECOVERY trial is testing multiple interventions in a broad population of patients hospitalised with COVID-19. The protocol and statistical analysis plan outline the methods that are to be used in the analysis of these interventions. With the exception of REGEN-COV2 (see Appendix I), the same approach has been used for all completed comparisons. However, it is important that the statistical analysis plan be informed by the best available information about the treatment being tested<sup>1</sup> and the pathophysiology of the disease.

At the point at which sotrovimab was added to the protocol (protocol version 21.1; approved 20<sup>th</sup> December 2021), the number of infections with the omicron variant of SARS-CoV-2 was rising exponentially, doubling approximately every 2 days. There was an enormous national effort to maximise vaccination such that by 20<sup>th</sup> December 2021, around 90% of adults aged >18 years had received a 1<sup>st</sup> dose of vaccine, 82% had received 2 doses, and 50% had received 3 doses (with around 0.5-1 million vaccine doses being administered each day). However, there were several important unknowns including the propensity for the omicron variant to cause severe disease, hospitalisation and death (either with or without vaccination).

The previous evaluation of REGEN-COV2 in RECOVERY had established that the monoclonal neutralising antibody combination was effective in patients who were seronegative, and no meaningful effect was seen among those who were seropositive. However, that evaluation was carried out prior to the emergence of the omicron variant and at a point when <10% participants had any vaccine dose (and almost nobody had had more than one). Hence, seropositive status at that time largely reflected an acute immune response to the active SARS-CoV-2 infection. By December 2021, the situation was more complicated – seropositive status could reflect an acute immune response (as before) or a legacy effect of prior infection (with a different variant) or prior vaccination (against a different variant). Given the immune escape demonstrated by omicron, it is reasonable to expect that at least some seropositive patients may benefit from treatment with a neutralising monoclonal antibody in the form of sotrovimab or an anti-viral treatment such as molnupiravir or paxlovid.

There is some evidence from the ACTIV-3 study programme<sup>2</sup> that serum viral antigen concentration may be a useful predictor of both poor outcome and of response to monoclonal neutralising antibody treatment. Serum samples will be collected and analysed for both anti-SARS-CoV-2 antibody concentration and viral antigen concentrations. The TSC will review data on the distribution of these and their association with primary and secondary outcomes (blinded to information about treatment allocation) before determining the most scientifically and clinically relevant primary analysis population.<sup>3</sup> (For example, the TSC might determine that the primary analysis should be restricted to those patients who are anti-N antibody negative or alternatively who have high viral antigen load, and decide on an analysis approach analogous to that used for patients who were seronegative [anti-S antibody negative] in the REGEN-COV2 analysis.)

For the avoidance of doubt, all decisions about this modification to the analytical plan will be made before recruitment is complete and before any members of the trial steering committee (who are responsible for drafting and approving the SAP) or investigators have

access to any unblinded analyses of clinical outcome data for the sotrovimab, molnupiravir and paxlovid comparisons. No members of the independent Data Monitoring Committee (who are the only individuals who can review interim unblinded analyses) will be involved in this decision.

### 13.2 References

1. Food and Drug Administration. E9 Statistical Principles for Clinical Trials. 1998.
2. ACTIV-3/TICO Study Group. The Association of Baseline Plasma SARS-CoV-2 Nucleocapsid Antigen Level and Outcomes in Patients Hospitalized With COVID-19. *Ann Intern Med* 2022;M22-0924.
3. Food and Drug Administration. Enrichment strategies for clinical trials to support determination of effectiveness of human drugs and biological products - guidance for industry. 2019.

## 14 APPROVAL

Trial Statistician	Name: Dr Natalie Staplin	
	Signature:	Date:
Trial Statistician	Name: Dr Jonathan Emberson	
	Signature:	Signature:
Chief Investigator	Name: Professor Peter Horby	
	Signature:	Date:
Deputy Chief Investigator	Name: Professor Martin Landray	
	Signature:	Date:
Steering Committee Statistician	Name: Professor Edmund Juszcak	
	Signature:	Date:
Steering Committee Statistician	Name: Professor Alan Montgomery	
	Signature:	Date:
Steering Committee Statistician	Name: Professor Thomas Jaki	
	Signature:	Date:

## 15 DOCUMENT HISTORY

Version	Date	Edited by	Comments/Justification	Timing in relation to unblinded interim monitoring	Timing in relation to unblinding of Trial Statisticians
0.1	20/03/20	LL/JB	First draft.	Prior	Prior
0.2	01/04/20	LL/JB	Comments and amendments from Martin Landray, Jonathan Emberson & Natalie Staplin. Also aligned with updated protocol and CRFs.	Prior	Prior
0.3	01/04/20	EJ/LL	Further edits and comments.	Prior	Prior
0.4	07/04/20	JB/EJ/LL	Following statistics group meeting on 02/04/20.	Prior	Prior
0.5	22/04/20	JB/LL/EJ	Following statistics group meeting on 09/04/20 and further protocol update.	After	Prior
0.6	24/04/20	LL	Following statistics group meeting on 23/04/20.	After	Prior
0.7	10/05/20	LL	Protocol update.	After	Prior
0.8	15/05/20	LL	Following statistics group meeting on 15/05/20.	After	Prior
0.9	27/05/20	LL	Further comments from TSC members prior to interim analysis on 28/05/20.	After	Prior
1.0	09/06/20	LL	Revised following the stopping of the hydroxychloroquine arm, and prior to the trial statisticians receiving unblinded data for this arm.	After	Prior
1.1	21/06/20	LL/JB/RH	Additional clarification of ventilation denominators. Adjustment for any imbalances of subgroup characteristics between treatment arms at randomisation. Clarification of analysis of composite outcome. Removal of 'Unknown' ethnicity subgroup. Addition of section 5.5 Adjustment for baseline characteristics.	After	After unblinding of hydroxychloroquine and dexamethasone arms.

Version	Date	Edited by	Comments/Justification	Timing in relation to unblinded interim monitoring	Timing in relation to unblinding of Trial Statisticians
2.0	04/11/20	EJ/ES	Revised to reflect changes in protocol, including introduction of factorial randomisations and new arms, including convalescent plasma, tocilizumab, synthetic neutralizing antibodies (REGEN-COV2, and aspirin.	Prior to interim analysis of aspirin arm  After interim analyses of all other arms	After unblinding of 28-day results for hydroxychloroquine, lopinavir-ritonavir, and dexamethasone arms.  Prior to unblinding of any other arms
2.1	02/12/20	ES	Addition of colchicine. Modification of definition of recipient antibody concentration subgroup.	Prior to interim analyses including antibody results or of colchicine arm.	After unblinding of 28-day results for hydroxychloroquine, lopinavir-ritonavir, and dexamethasone arms.  Prior to unblinding of any other arms
2.2	27/01/21	ES	Clarification of non-invasive ventilation-related subgroups. Addition of baricitinib.	Prior to interim analyses of baricitinib arm.	After unblinding of 28-day results for hydroxychloroquine, lopinavir-ritonavir, azithromycin and dexamethasone arms (and primary outcome in overall population in convalescent plasma arm).  Prior to unblinding of any other arms

Version	Date	Edited by	Comments/Justification	Timing in relation to unblinded interim monitoring	Timing in relation to unblinding of Trial Statisticians
3.0	15/05/21	ES	Specification of method for REGEN-COV2 comparison (appendix A). Addition of early phase assessment of dimethyl fumarate. Addition of infliximab and high-dose corticosteroids.	Prior to interim analyses of infliximab or high-dose steroids.	After unblinding of 28-day results for hydroxychloroquine, lopinavir-ritonavir, azithromycin, dexamethasone, colchicine and convalescent plasma arms.  Prior to unblinding of any other arms.
3.1	29/10/21	RH	Modification of early phase assessments to align with protocol V18.1 Modification of 6 months analysis section.	Prior to early phase assessments or 6 month analyses.	Prior to unblinding of dimethyl fumarate or 6 month outcome data.
3.2	17/12/21	RH	Update to early phase assessments	Prior to 6 month analyses	Prior to unblinding of dimethyl fumarate
4.0	20/09/22	MJL	Revised to reflect changes in protocol versions 19-25. Now includes information on comparisons for influenza and for sotrovimab, molnupiravir and paxlovid. Update to 6 month and long-term assessments.	Prior to interim analyses of these arms.	Prior to commencement of enrolment to influenza comparisons. Prior to unblinding of sotrovimab, molnupiravir, paxlovid, empagliflozin, and high dose corticosteroid comparisons for participants on non-invasive ventilation or invasive mechanical ventilation.